טוען...
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
BACKGROUND: Amyloid-β positron emission tomography (PET) and cerebrospinal fluid (CSF) Aβ(42) are considered interchangeable for clinical diagnosis of Alzheimer’s disease. OBJECTIVE: To explore the clinical reasoning for requesting additional amyloid-β PET after performing CSF biomarkers. METHODS: W...
שמור ב:
| הוצא לאור ב: | J Alzheimers Dis |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
IOS Press
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7081099/ https://ncbi.nlm.nih.gov/pubmed/31796674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-190836 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|